


## SNS-314

<b>Cat. No.:</b>	HY-108344
<b>CAS No.:</b>	1057249-41-8
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>15</sub> ClN <sub>6</sub> OS <sub>2</sub>
<b>Molecular Weight:</b>	430.93
<b>Target:</b>	Aurora Kinase
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SNS-314 is a potent and selective aurora kinase inhibitor with IC <sub>50</sub> s of 9, 31, and 6 nM for aurora A, B and C, respectively <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	Aurora A 9 nM (IC <sub>50</sub> )	Aurora B 31 nM (IC <sub>50</sub> )	Aurora C 6 nM (IC <sub>50</sub> )
<b>In Vitro</b>	SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC <sub>50</sub> values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
<b>In Vivo</b>	In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Patent. US20180263995A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Oslob JD, et al. Discovery of a potent and selective aurora kinase inhibitor. *Bioorg Med Chem Lett*. 2008 Sep 1;18(17):4880-4.

[2]. Arbitrario JP, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. *Cancer Chemother Pharmacol*. 2010 Mar;65(4):707-17.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA